LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

49.12 3.76

Overview

Share price change

24h

Current

Min

48.52

Max

49.12

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+5.88% upside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

309M

2.9B

Previous open

45.36

Previous close

49.12

News Sentiment

By Acuity

50%

50%

127 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

15 Feb 2026, 23:21 UTC

Acquisitions, Mergers, Takeovers

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 Feb 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 Feb 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 Feb 2026, 23:06 UTC

Earnings

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 Feb 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 Feb 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 Feb 2026, 23:01 UTC

Earnings

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 Feb 2026, 23:01 UTC

Earnings

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 Feb 2026, 22:58 UTC

Earnings

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

15 Feb 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 Feb 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 Feb 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Shareholders to Receive A$5.20/Share in Cash

15 Feb 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 Feb 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 Feb 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 Feb 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 Feb 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 Feb 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 Feb 2026, 21:35 UTC

Earnings

Warner Bros. Lands Ninth Straight Box Office Winner With 'Wuthering Heights' -- Barrons.com

15 Feb 2026, 20:48 UTC

Earnings

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 Feb 2026, 20:47 UTC

Earnings

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 Feb 2026, 20:46 UTC

Earnings

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 Feb 2026, 20:45 UTC

Earnings

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 Feb 2026, 20:44 UTC

Earnings

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 Feb 2026, 20:44 UTC

Earnings

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 Feb 2026, 20:43 UTC

Earnings

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 Feb 2026, 20:42 UTC

Earnings

BlueScope Net Debt A$2.2 Million at Dec. 31

15 Feb 2026, 20:42 UTC

Earnings

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 Feb 2026, 20:41 UTC

Earnings

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 Feb 2026, 20:40 UTC

Earnings

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

5.88% upside

12 Months Forecast

Average 52 USD  5.88%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

127 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat